| 208.98 -3.83 (-1.8%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 251.76 |
1-year : | 268.56 |
| Resists | First : | 215.55 |
Second : | 229.94 |
| Pivot price | 207.31 |
|||
| Supports | First : | 192.27 |
Second : | 159.97 |
| MAs | MA(5) : | 208.08 |
MA(20) : | 207.2 |
| MA(100) : | 202.06 |
MA(250) : | 0 | |
| MACD | MACD : | 0.7 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 47.9 |
D(3) : | 44.4 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 229.94 | Low : | 118.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ASND ] has closed below upper band by 43.2%. Bollinger Bands are 18% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 214.16 - 215.24 | 215.24 - 216.13 |
| Low: | 205.66 - 206.8 | 206.8 - 207.73 |
| Close: | 207.32 - 209.1 | 209.1 - 210.55 |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Thu, 25 Dec 2025
Ascendis Pharma A/S $ASND Shares Sold by Harbor Capital Advisors Inc. - MarketBeat
Thu, 25 Dec 2025
ARS Investment Partners LLC Decreases Stock Position in Ascendis Pharma A/S $ASND - MarketBeat
Tue, 23 Dec 2025
Squarepoint Ops LLC Buys Shares of 5,197 Ascendis Pharma A/S $ASND - MarketBeat
Tue, 16 Dec 2025
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today - Sahm
Mon, 15 Dec 2025
Here’s My Prediction For Who Could Acquire Ascendis Pharma (NASDAQ:ASND) - Seeking Alpha
Fri, 12 Dec 2025
Ascendis Pharma Stock: Analyst Boosts Price Target Amid Sector Surge - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 106.1 (%) |
| Shares Short | 3,300 (K) |
| Shares Short P.Month | 3,550 (K) |
| EPS | -4.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.34 |
| Profit Margin | -36.1 % |
| Operating Margin | 5.1 % |
| Return on Assets (ttm) | -7.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 269.3 % |
| Gross Profit (p.s.) | 9.18 |
| Sales Per Share | 10.58 |
| EBITDA (p.s.) | -2.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -107 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | -46.76 |
| PEG Ratio | 0 |
| Price to Book value | -62.57 |
| Price to Sales | 19.74 |
| Price to Cash Flow | -119.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|